Show simple item record

dc.contributor.authorCurley, Clive J.
dc.contributor.authorDolan, Eimear B.
dc.contributor.authorOtten, Matthias
dc.contributor.authorHinderer, Svenja
dc.contributor.authorDuffy, Garry P.
dc.contributor.authorMurphy, Bruce P.
dc.date.accessioned2019-05-22T11:24:01Z
dc.date.issued2018-12-03
dc.identifier.citationCurley, Clive J., Dolan, Eimear B., Otten, Matthias, Hinderer, Svenja, Duffy, Garry P., & Murphy, Bruce P. (2019). An injectable alginate/extra cellular matrix (ECM) hydrogel towards acellular treatment of heart failure. Drug Delivery and Translational Research, 9(1), 1-13. doi: 10.1007/s13346-018-00601-2en_IE
dc.identifier.issn2190-3948
dc.identifier.urihttp://hdl.handle.net/10379/15191
dc.description.abstractAs treatments for myocardial infarction (MI) continue to improve, the population of people suffering from heart failure (HF) is rising significantly. Novel treatment strategies aimed at achieving long-term functional stabilisation and improvement in heart function post MI include the delivery of biomaterial hydrogels and myocardial matrix-based therapies to the left ventricle wall. Individually alginate hydrogels and myocardial matrix-based therapies are at the most advanced stages of commercial/clinical development for this potential treatment option. However, despite these individual successes, the potential synergistic effect gained by combining the two therapies remains unexplored. This study serves as a translational step in evaluating the minimally invasive delivery of dual acting alginate-based hydrogels to the heart. We have successfully developed new production methods for hybrid alginate/extracellular matrix (ECM) hydrogels. We have identified that the high G block alginate/ECM hybrid hydrogel has appropriate rheological and mechanical properties (1.6 KPa storage modulus, 29 KPa compressive modulus and 14 KPa dynamic modulus at day 1) and can be delivered using a minimally invasive delivery device. Furthermore, we have determined that these novel hydrogels are not cytotoxic and are capable of enhancing the metabolic activity of dermal fibroblasts in vitro (p < 0.01). Overall these results suggest that an effective minimally invasive HF treatment option could be achieved by combining alginate and ECM particles.en_IE
dc.description.sponsorshipAMCARE project funded by European Union’s ‘Seventh Framework’ Programme for research, technological development and demonstration under Grant Agreement no. NMP3-SME-2013-604531.en_IE
dc.formatapplication/pdfen_IE
dc.language.isoenen_IE
dc.publisherSpringer Verlagen_IE
dc.relation.ispartofDrug Delivery And Translational Researchen
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Ireland
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/3.0/ie/
dc.subjectHeart failureen_IE
dc.subjectAcellular hydrogelen_IE
dc.subjectMinimally invasive delivery catheteren_IE
dc.subjectAlginateen_IE
dc.subjectDecellularizeden_IE
dc.subjectECMen_IE
dc.titleAn injectable alginate/extra cellular matrix (ECM) hydrogel towards acellular treatment of heart failureen_IE
dc.typeArticleen_IE
dc.date.updated2019-05-22T07:51:57Z
dc.identifier.doi10.1007/s13346-018-00601-2
dc.local.publishedsourcehttps://doi.org/10.1007/s13346-018-00601-2en_IE
dc.description.peer-reviewedpeer-reviewed
dc.contributor.funderSeventh Framework Programmeen_IE
dc.description.embargo2019-12-03
dc.internal.rssid15526891
dc.local.contactEimear Dolan, Biomedical Engineering 3031, College Of Engineering & Informa, Nui Galway. Email: eimear.dolan@nuigalway.ie
dc.local.copyrightcheckedYes
dc.local.versionACCEPTED
dcterms.projectinfo:eu-repo/grantAgreement/EC/FP7::SP1::NMP/604531/EU/Advanced Materials for Cardiac Regeneration (AMCARE)/AMCAREen_IE
nui.item.downloads605


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 Ireland
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Ireland